LC-MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-09. Numbers and descriptions here follow the published literature rather than marketing material.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
CB03-154 is a Kv7.2 and Kv7.3 potassium channel opener which is under development for the treatment of amyotrophic lateral sclerosis (ALS), epilepsy, major depressive disorder, bipolar disorders, stroke, and pain in China. It is taken orally. The drug is said to have higher selectivity and stability compared to retigabine. CB03-154 is under development by Shanghai Zhimeng Biopharma. As of November 2025, it is in 2/3 clinical trials for ALS, phase 2 trials for epilepsy and major depressive disorder, phase 1 trials for bipolar disorders, and the preclinical research stage of development for stroke, whereas no recent development has been reported for pain.
Alpha-synuclein primary structure is usually divided in three distinct domains: Residues 1-60: An amphipathic N-terminal region dominated by four 11-residue repeats including the consensus sequence KTKEGV. This sequence has a structural alpha helix propensity similar to apolipoproteins-binding domains. It is a highly conserved terminal that interacts with acidic lipid membranes, and all the discovered point mutations of the SNCA gene are located within this terminal. Residues 61-95: A central hydrophobic region which includes the non-amyloid-β component (NAC) region, involved in protein aggregation. This domain is unique to alpha-synuclein among the synuclein family. Residues 96-140: a highly acidic and proline-rich region which has no distinct structural propensity. This domain plays an important role in the function, solubility and interaction of alpha-synuclein with other proteins.
== Oxygen-18 == Oxygen-18 (18O, Ω) is one of the stable isotopes of oxygen, with roughly 0.20% abundance, and considered one of the environmental isotopes. Most 18O is produced when 14N (made abundant from CNO burning) captures a 4He nucleus, becoming 18F. This quickly (half-life around 110 minutes) beta decays to 18O making that isotope common in the helium-rich zones of stars. Temperatures on the order of 109 kelvins are needed to fuse oxygen into sulfur. Fluorine-18 is usually produced by irradiation of 18O-enriched water with high-energy (about 18 MeV) protons prepared in a cyclotron or a linear accelerator, yielding an aqueous solution containing 18F as fluoride ion. This solution is then used for rapid synthesis of a labeled molecule, often with the fluorine atom replacing a hydroxy group. The labeled molecules or radiopharmaceuticals have to be synthesized after the radiofluorine is prepared, as the high energy proton radiation would destroy the molecules. Large amounts of oxygen-18 enriched water are used in positron emission tomography centers, for on-site production of 18F-labeled fluorodeoxyglucose (FDG). Measurements of the 18O/16O ratio (known as δ18O) are often used in paleoclimatology. Water molecules with a lighter isotope are slightly more likely to evaporate and less likely to fall as precipitation, so Earth's freshwater and polar ice have slightly less (0.1981%) 18O than air (0.204%) or seawater (0.1995%). This disparity allows the study of historical temperature patterns via the analysis of ice cores.
== Premise == The show's plot centers around the lives of half-sisters Mona and Dee Dee Thorne, who slowly become friends when they move into the same San Francisco apt building. Mona is the daughter of Phyllis Thorne, Charles Thorne's first wife, and Dee Dee is Charles' daughter from his second marriage to Deirdre "Big Dee Dee" Thorne. Initially, Mona resents Dee Dee because Dee Dee grew up in a wealthy and privileged household, while Mona and her mother struggled financially. As adults, Mona is more street-smart and cynical, but prone to impulsive decisions while Dee Dee is charming and optimistic, but naïve at times. Throughout the series, the sisters confront their past resentments and learn to lean on each other as they navigate their issues in work, love, and family.
The best-characterized reference (“type”) strain of S. boulardii is CBS 5926, which is also deposited under the culture collection numbers ATCC 74012 and CNCM I-745. This strain dominates commercial use of S. boulardii and is produced by the pharmaceutical company Biocodex; it has been evaluated in more than 90 randomized clinical trials. In addition to CNCM I-745, several manufacturers market S. boulardii supplements derived from distinct, often proprietary strains, including CNCM I-1079, CNCM I-3799, and DBVPG 6763, although it remains unclear whether it is genetically identical to CBS 5926.
Sources: en.wikipedia.org
Many acupuncturists have argued that dry needling appears to be an acupuncture technique requiring minimal training that has been re-branded under a new name (dry needling). Whether dry needling is considered to be acupuncture depends on the definition of acupuncture, and it is argued that trigger points do not correspond to acupuncture points or meridians. They correspond by definition to the ad hoc category of 'a-shi' acupoints. This category of points is not necessarily distinct from other formal categories of acupoints. In 1983, Janet Travell described trigger point locations as 92% in correspondence with known acupuncture points. In 2006, a journal article concluded that the two point systems are in over 90% agreement. In 2009, Dorsher and Fleckenstein conclude that the strong (up to 91%) consistency of the distributions of trigger point regions' referred pain patterns to acupuncture meridians provides evidence that trigger points most likely represent the same physiological phenomenon as acupuncture points in the treatment of pain disorders. A comparison of Western trigger points to traditional acupuncture points corroborates the 92% correspondence. In 2011, The Council of Colleges of Acupuncture and Oriental Medicine published a position paper describing dry needling as an acupuncture technique. According to a qualitative review, dry needling combined with acupuncture was more effective in alleviating pain and achieved a higher response rate than dry needling alone.
Polyvinylene carbonate is readily soluble in acetone and dimethylformamide. The solutions obtained, however, tend to decompose already at room temperature. The patent literature describes the use of polyvinyl carbonate for strong fibers, clear, colorless and mechanically strong films, membranes for reverse osmosis and as support during affinity chromatography. In addition to the instability in solutions, polyvinyl carbonate has the tendency towards hydrolysis in weakly alkaline medium. This forms polyhydroxymethylene (PHM) via cleavage of the cyclic carbon ring, with the repeating unit –(CHOH)–. Its behavior is much more similar to cellulose than to the structurally related polyvinyl alcohol with the repeating unit –(CH2–CHOH)–.
Mukasey (1963), attorney general of the United States; former chief judge of the United States District Court for the Southern District of New York David Saxe (1963), associate justice of the Appellate Division of the New York Supreme Court, First Judicial Department and former judge on the New York Supreme Court Peter Zimroth (1963), assistant U.S. attorney for the Southern District of New York and assistant New York County district attorney, professor at the New York University School of Law Barry Kamins (1965), New York City Criminal Court judge and professor at the Fordham University School of Law and Brooklyn Law School Howard Matz (1965), senior judge of the United States District Court for the Central District of California Flemming L. Norcott Jr. (1965), former associate justice of the Connecticut Supreme Court Joel Klein (1967), assistant attorney general of the United States; chancellor of the New York City Department of Education Anthony C. Moscato (1967), acting inspector general of the Department of Justice and director of the Executive Office for United States Attorneys David M. Becker (1968), two-time general counsel of the U.S. Securities and Exchange Commission Nicholas G. Garaufis (1969), judge of the United States District Court for the Eastern District of New York and former chief counsel of the Federal Aviation Administration Jonathan D.
=== Creation of the covidSHIELD assay and SHIELD Illinois === The University of Illinois at Urbana-Champaign (UIUC) faced a problem when the global spread of SARS-CoV-2 and COVID-19 led to the closure of its campus in April 2020. Campus leaders wanted to find a way to resume normal activities and realized that frequent, accurate testing of the community would be key. However, there was no existing test that was non-invasive, inexpensive, and quick enough to provide results in time for the campus to take action. UIUC decided to take on this challenge and within a few months, researchers had developed the covidSHIELD assay, a saliva-based PCR test that eliminated the costly and time-consuming RNA extraction step used in other SARS-CoV-2 tests. This fast, accurate, and affordable test allowed UIUC to start twice weekly testing of its entire campus population, which helped to reduce the positivity rate on campus and in the surrounding community. The success of the SHIELD program at UIUC led the University of Illinois System to offer this service to other entities in Illinois, resulting in the creation of the SHIELD Deployment Unit aka SHIELD Illinois. To run this new startup, University administration tapped then Associate Dean for Strategy and Innovation at the Gies College of Business on the Urbana-Champaign campus, Ron Watkins. Watkins brought on board three former iMBA students to form the core team along with individuals loaned to SHIELD Illinois by other system units.
=== Mental health === Evidence suggests that mental health can be a significant facilitator for opioid use disorder. Given that opioids are prescribed for pain management, mental health disorders, such as depression, have been shown to increase use of opioids when treating conditions associated with chronic pain. Evidence has shown that individuals with mood and anxiety disorders have an increased likelihood of being prescribed opioids and continuing usage for lengthy periods of time, consequently increasing likelihood for dependence. As such, affected individuals have almost double the risk of using opioids for pain relief in the long-term. Additionally, mental health challenges associated with trauma, economic depression, social environments conducive to substance use and risk-taking behaviours have been shown to increase opioid misuse. Furthermore, mental health challenges associated with cardiovascular disease, sleep disorders, and HIV can cause opioid dependence and subsequent overdose. Notably, cyclic behaviours can be observed between mental illness and opioid use disorder where individuals with mental health diagnoses engage in opioid use which further perpetuates mental health challenges and increased drug usage.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.